How to buy Inovio Pharmaceuticals shares

Own Inovio Pharmaceuticals shares in just a few minutes.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Inovio Pharmaceuticals, Inc is a biotechnology business with stocks listed in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$7.94 – an increase of 5.17% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Inovio Pharmaceuticals

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Inovio Pharmaceuticals. Find the share by name or ticker symbol: INO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Inovio Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$7.94, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Inovio Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Inovio Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Inovio Pharmaceuticals share price

Use our graph to track the performance of INO stocks over time.

Inovio Pharmaceuticals shares at a glance

Information last updated 2021-06-10.
52-week rangeUS$5.81 - US$33.79
50-day moving average US$7.2937
200-day moving average US$9.7903
Target priceUS$14
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-1.215

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Inovio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Inovio Pharmaceuticals price performance over time

Historical closes compared with the last close of $7.94

1 week (2021-06-08) -7.57%
1 month (2021-05-14) 21.22%
3 months (2021-03-15) -24.02%
6 months (2020-12-15) -27.26%
1 year (2020-06-15) -43.89%
2 years (2019-06-14) 229.46%
3 years (2018-06-15) 76.84%
5 years (2016-06-15) -25.72%

Inovio Pharmaceuticals financials

Revenue TTM US$6.5 million
Gross profit TTM US$-86,834,216
Return on assets TTM -19.04%
Return on equity TTM -49.06%
Profit margin 0%
Book value 2.778
Market capitalisation US$1.9 billion

TTM: trailing 12 months

Shorting Inovio Pharmaceuticals shares

There are currently 50.9 million Inovio Pharmaceuticals shares held short by investors – that's known as Inovio Pharmaceuticals's "short interest". This figure is 9.1% down from 56.0 million last month.

There are a few different ways that this level of interest in shorting Inovio Pharmaceuticals shares can be evaluated.

Inovio Pharmaceuticals's "short interest ratio" (SIR)

Inovio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Inovio Pharmaceuticals shares currently shorted divided by the average quantity of Inovio Pharmaceuticals shares traded daily (recently around 6.4 million). Inovio Pharmaceuticals's SIR currently stands at 7.9. In other words for every 100,000 Inovio Pharmaceuticals shares traded daily on the market, roughly 7900 shares are currently held short.

However Inovio Pharmaceuticals's short interest can also be evaluated against the total number of Inovio Pharmaceuticals shares, or, against the total number of tradable Inovio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovio Pharmaceuticals's short interest could be expressed as 0.24% of the outstanding shares (for every 100,000 Inovio Pharmaceuticals shares in existence, roughly 240 shares are currently held short) or 0.2473% of the tradable shares (for every 100,000 tradable Inovio Pharmaceuticals shares, roughly 247 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Inovio Pharmaceuticals.

Find out more about how you can short Inovio Pharmaceuticals stock.

Inovio Pharmaceuticals share dividends

We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months.

Have Inovio Pharmaceuticals's shares ever split?

Inovio Pharmaceuticals's shares were split on a 1:4 basis on 5 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.

Inovio Pharmaceuticals share price volatility

Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as US$5.81 up to US$33.79. A popular way to gauge a stock's volatility is its "beta".

INO.US volatility(beta: 0.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 0.6549. This would suggest that Inovio Pharmaceuticals's shares are less volatile than average (for this exchange).

Inovio Pharmaceuticals overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquart

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform